Kidney Cancer Drugs Market Size

Kidney Cancer Drugs Market size is estimated at USD 6.9 billion in 2024 and is expected to exceed USD 13.46 billion by the end of 2037, expanding at over 5.5% CAGR during the forecast period i.e., between 2025-2037. In 2025, the industry size of kidney cancer drugs is evaluated at USD 7.09 billion.

The primary growth driver of the kidney cancer drugs market is the increasing incidence of kidney cancer worldwide. As the number of diagnosed cases rises, a huge demand for effective treatments fuels demand for new and improved therapies. According to a 2024 report by the National Library of Medicine, kidney cancer (renal cancer) is a disease with an increasing global incidence of 400000 new cases per year and a mortality rate of approximately 175000 deaths per year.

Moreover, kidney cancer drug manufacturers are investing heavily in research and development activities for the production of innovative solutions. Companies investing in R&D are able to develop new drugs and therapies, including targeted treatments, immunotherapies, and combination therapies. These innovations address unmet medical needs and offer improved efficacy, safety, and convenience, expanding the range of available treatment options. For instance, Merck & Co's R&D investment strategy focuses on immuno-oncology, notably the development of its portfolio following the success of its popular cancer treatment, Keytruda (pembrolizumab).